EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing

Marisa H Blackman, Bradley Yelvington, Cole Beck, Manuel Cortez, Leena Choi

European Journal of Clinical Pharmacology · 2026

DOI: 10.1007/s00228-026-04080-0 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Marisa H Blackman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. Hauptthemen laut MEDLINE: Methotrexate, Models, Biological, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health (NIH)/National Institute of General Medical Sciences, NIH/National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

High-dose methotrexate is an effective treatment for adult and pediatric patients with acute lymphoblastic leukemia, osteosarcoma, and lymphoma. However, its clearance is highly variable, and delayed clearance can lead to significant toxicity. This study aimed to identify a population pharmacokinetic model that accurately characterizes high-dose methotrexate clearance in an adult population.

Methods

We developed a new population pharmacokinetic model using a training dataset derived from a cohort of 208 adult patients who received high-dose methotrexate at Vanderbilt University Medical Center. To assess predictive performance, we evaluated both our model and several externally developed models using an independent test dataset.

Results

The final model was a three-compartment model incorporating body surface area as a covariate on all pharmacokinetic parameters, and serum creatinine and sex as covariates on clearance. Our newly developed model predicted with the most accuracy and precision at the first concentration measurement, taken at 24 h. Our model, along with five external models, was selected based on predictive performance for further assessment with maximum a posteriori Bayesian forecasting to compare predictions at the individual-level. The model by Hui et al. was more accurate at 48 h, while our model performed similarly at 72 h.

Conclusion

These findings suggest an optimal strategy for therapeutic drug monitoring and dosing decisions: use our model for prediction at the 24 h mark when no prior drug levels are available, followed by Bayesian forecasting using our new model supplemented by the Taylor model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateModels, BiologicalAntimetabolites, AntineoplasticHumansFemaleMaleAdultBayes TheoremMiddle AgedYoung AdultCreatinineAgedDose-Response Relationship, DrugDrug MonitoringBody Surface Area

Stichwörter der Autor:innen

CancersModel evaluationPharmacokineticsPharmacometrics

Substanzen

MethotrexateAntimetabolites, AntineoplasticCreatinine

Autor:innen und Institutionen

  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Department of Oncology Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Department of Pharmacy, Rush MD Anderson Cancer Center, Chicago, IL, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. leena.choi@vumc.org.

Förderung

  • National Institute of Health (NIH)/National Institute of General Medical Sciences
  • NIH/National Institute of Child Health and Human Development

Zitieren

APA

Blackman, M. H., Yelvington, B., Beck, C., Cortez, M., & Choi, L. (2026). Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04080-0

Vancouver

Blackman MH, Yelvington B, Beck C, Cortez M, Choi L. Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-026-04080-0

BibTeX
@article{Blackman2026,
  author = {Blackman, Marisa H and Yelvington, Bradley and Beck, Cole and Cortez, Manuel and Choi, Leena},
  title = {Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1007/s00228-026-04080-0}
}
Kostenlos starten →